New Partners to Develop Immune Engagers.
A development deal between Genentech and Affimed will boost research on immune-cell engagers. The agents, which are composed of two or more linked antibody fragments that bridge immune cells and cancer cells, stimulate the cytotoxic activity of T cells and natural killer cells.